A meta-analysis of 32 studies found that using both ultrasound and alpha-fetoprotein (AFP) detected early-stage HCC with only 63% sensitivity, and 47% sensitivity with ultrasound alone.
Undertaking surveillance with AFP alone missed most early-stage disease.5
A meta-analysis assessing patient adherence to HCC surveillance found that surveillance utilization is estimated at 24%.4
The Oncoguard® Liver solution is exactly what’s needed to bridge gaps in HCC detection
For healthcare providers
The Oncoguard® Liver solution offers a powerful combination of performance, accessibility, and adherence support for a streamlined approach to HCC detection.
Learn about the science, applicability, and logistics of the Oncoguard® Liver solution.